CN102349877A - Hydroxychloroquine sulfate capsule, hydroxychloroquine sulfate dispersible tablet and application thereof - Google Patents
Hydroxychloroquine sulfate capsule, hydroxychloroquine sulfate dispersible tablet and application thereof Download PDFInfo
- Publication number
- CN102349877A CN102349877A CN201110324985XA CN201110324985A CN102349877A CN 102349877 A CN102349877 A CN 102349877A CN 201110324985X A CN201110324985X A CN 201110324985XA CN 201110324985 A CN201110324985 A CN 201110324985A CN 102349877 A CN102349877 A CN 102349877A
- Authority
- CN
- China
- Prior art keywords
- parts
- hydroxychloroquine sulfate
- capsule
- dispersible tablet
- hydroxychloroquine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to new preparation of hydroxychloroquine sulfate and particularly provides a hydroxychloroquine sulfate capsule and a hydroxychloroquine sulfate dispersible tablet, belonging to the field of medicine technology. One hundred parts of, by weight, hydroxychloroquine sulfate capsule, comprises the ingredients of, 30-40 parts of hydroxychloroquine sulfate crude drug, 3-8 parts of magnesium stearate, 3-8 parts of talcum powder, 1-5 parts of glycerol and the balance of auxiliary materials. One hundred parts of, by weight, hydroxychloroquine sulfate dispersible tablet comprises the ingredients of 30-40 parts of hydroxychloroquine sulfate crude drug, 2-8 parts of disintegrating agent, 2-8 parts of flow agent, 2-8 parts of surfactant and the balance of auxiliary materials, wherein the disintegrating agent is polyvinylpyrrolidone, the flow agent is superfine silica powder and the surfactant is polysorbate 80. The new preparations provided by the invention effectively improve the use ratio of the drug and reduce the side effects of the drug, and different types of preparation of the drug are convenient for different patients to use.
Description
Technical field
The invention belongs to medical technical field, relate to a kind of clinical practice research of medicine novel form widely.
Background technology
In decades in the past, oxychloroquine in the antimalarial (HCQ) and chloroquine, the important drugs as therapy system property lupus erythematosus (SLE) and rheumatoid arthritis rheumatism such as (RA) is used to clinical always.In recent ten years, owing to recognizing that the extensive effect of oxychloroquine in immunomodulating becomes a research focus, also makes the effect of oxychloroquine in rheumatism treatment more and more come into one's own.Current research shows, hydroxychloroquine sulfate is a kind of safe and effective and antirheumatic of effect slowly that toleration is fabulous.
The hydroxychloroquine sulfate of present clinical use has only the dosage form of conventional tablet, and its bioavailability is not high, and it is not too convenient to use, and hydroxychloroquine sulfate needs the patient to take for a long time.
Summary of the invention
Deficiency to prior art; Under the prerequisite that guarantees medication effect and safety; We have proposed hydroxychloroquine sulfate capsule and two kinds of novel forms of hydroxychloroquine sulfate dispersible tablet; Can effectively improve the utilization rate of medicine, reduce side effects of pharmaceutical drugs, different dosage forms makes things convenient for different patients to use; Simultaneously; Carry out suitable technological transformation and can also reduce the production cost of medicine, thereby reduce drug price, alleviate patient's financial burden.
One of technical scheme that the present invention adopted:
A kind of hydroxychloroquine sulfate capsule comprises the composition of following weight portion in the hydroxychloroquine sulfate capsule of 100 weight portions:
3 parts-8 parts of 30 parts of-40 parts of magnesium stearate of hydroxychloroquine sulfate crude drug
1 part-5 parts of 3 parts of-8 parts of glycerol of Pulvis Talci
All the other are adjuvant.
Be preferably: the composition that comprises following weight portion in the hydroxychloroquine sulfate capsule of 100 weight portions:
5 parts of 23 parts of magnesium stearate of hydroxychloroquine sulfate crude drug
2 parts of 5 parts of glycerol of Pulvis Talci
All the other are adjuvant.
Said adjuvant is starch and/or PEG400.
The moisture content of the capsular content of said hydroxychloroquine sulfate is less than 9%.
Said hydroxychloroquine sulfate capsule is preferably capsule No. 2, and specification is the 0.1g/ grain.
Two of technical scheme of the present invention:
A kind of hydroxychloroquine sulfate dispersible tablet comprises the composition of following weight portion in the hydroxychloroquine sulfate dispersible tablet of 100 weight portions:
2 parts-8 parts of 30 portions of-40 portions of disintegrating agents of hydroxychloroquine sulfate crude drug
2 parts-8 parts in 2 parts of-8 parts of surfactants of fluidizer
All the other are adjuvant;
Said disintegrating agent is a polyvinylpyrrolidone, and said fluidizer is micropowder silica gel, and said surfactant is a polyoxyethylene sorbitan monoleate;
Said adjuvant is: starch, Pulvis Talci, mannitol, one or more in microcrystalline Cellulose and the sodium alginate.
Preferably: the composition that comprises following weight portion in the hydroxychloroquine sulfate dispersible tablet of 100 weight portions:
5 parts of 35 portions of disintegrating agents of hydroxychloroquine sulfate crude drug
5 parts in 5 parts of surfactants of fluidizer
All the other are adjuvant.
The application in the medicine of preparation treatment rheumatoid disease of hydroxychloroquine sulfate capsule of the present invention and hydroxychloroquine sulfate dispersible tablet.
Do further explanation and illustrate that the present invention develops two kinds of new dosage forms in the face of the present invention down:
1, hydroxychloroquine sulfate capsule:
Capsule has following characteristics: bad flavor, the raising medicine stability smelt that can cover medicine; In vivo rapid-action of medicine, its curative effect is higher than pill, tablets and other formulations generally speaking; Can delay release and positioning release medicine of medicine etc.Several steps below the main branch of this research:
(1) selection of capsulae vacuus: gelatin is the main one-tenth capsule material of capsulae vacuus.Separate and make by bone, the severe edema due to hypofunction of the spleen.Process by adjuvant for the gelatin of directly buying adds for the capsulae vacuus that the present invention tests employing.
(2) preparation of fill material: pure medicine is crushed to suitable granularity, adds the flowability that filleies such as magnesium stearate, Pulvis Talci improve material, avoid layering.
(3) selection of capsule specification and fit, seal: the method for employing is to measure earlier the bulk density of material to be filled, according to adorning this material volume of Rapid Dose Calculation, should select capsular count with decision then.Select the specification of capsulae vacuus, the clinical consumption of bound drug, No. 2 capsules of employing, drug specifications 0.1g/ grain according to the loading of medicine.After medicine is filled in utricule, can the fit capsule cap.We use fore shaft formula capsule, and seal is good, needn't seal.
The quality of capsule detects by the requirement to capsule in the pharmacopeia " rules of preparations ", and the result is following:
(1) outward appearance hydroxychloroquine sulfate capsule outward appearance is clean and tidy, no bonding, distortion or fracture phenomena, no foreign odor.Content is dry, appropriate, the mix homogeneously of degree of tightness.
(2) water content detection of moisture hydroxychloroquine sulfate hard capsule content is less than 9.0%.
(3) content uniformity is got 20 of test samples, and weight decided in accurate respectively title, and inclining content, and softgel shell is clean with little grooming, and precision is claimed to decide softgel shell weight respectively again, obtains the loading amount of every capsules content and 20 average loading amount.Every loading amount is compared with average loading amount, exceeds no more than 2 of content uniformity limit, does not have one times of an overrun.
(4) disintegration and dissolution carry out disintegration and dissolution test by experimental technique, and be up to specification.
(5) assay:
Instrument: day island proper Tianjin high performance liquid chromatograph;
The hydroxychloroquine sulfate reference substance: Shanghai Westen and Chinese Tranditional Medicine Pharamacentic Co., Ltd produces, content 99.9%, and 105 ℃ are dried to constant weight during use.Get hydroxychloroquine sulfate reference substance 50mg, accurate claim surely, put in the 50mL measuring bottle, with the chromatograph dissolve with methanol and be diluted to graduation mark, shake up, promptly get.
Chromatographic condition: chromatographic column: shim-pack vp-ODS post; Mobile phase: 0.05mol.L
-1Potassium dihydrogen phosphate (containing 1.0% triethylamine)-0.005mol.L
-1The sodium heptanesulfonate methanol solution; Detect wavelength: 343nm; Flow velocity: 1.0mL/min; Column temperature: room temperature; Sample size: 20 μ L.
Sample treatment: get 50 of homemade hydroxychloroquine sulfate capsules, be dried to constant weight, porphyrize, precision takes by weighing 3 parts in an amount of sample (being equivalent to hydroxychloroquine sulfate 50mg), puts respectively in the 50mL measuring bottle, with the chromatograph dissolve with methanol and be diluted to graduation mark, shakes up, and promptly gets.
Measure: get reference substance solution and 3 parts of need testing solutions carry out chromatography, calculate content by external standard method, the result shows that the content of 3 duplicate samples is respectively 93.5%, 93.1%, 93.6%.RSD (relative standard deviation) is respectively 0.88%, 0.90%, 0.85%.
2, hydroxychloroquine sulfate dispersible tablet:
Dispersible tablet means in water the homodisperse tablet of disintegrate rapidly.With respect to solid preparations such as conventional tablet, capsules, dispersible tablet have taking convenience, disintegrate rapidly, absorb characteristics such as fast and bioavailability height.It has simple, the taking convenience of preparation, can reduce medicine untoward reaction, improve advantage such as drug bioavailability.The prescription of these article designs as follows:
(1) disintegrating agent and suspending agent: the general disintegrating agent swellbility that requires to select for use should be greater than 5mlg.Experiment serves as to investigate kind and the best proportioning that index adopts uniform Design method screening disintegrating agent with disintegration time, suspension ability or uniformity, the stripping etc. of dispersible tablet.Because it is relatively large that its capillary activity of polyvinylpyrrolidone (PVPP) is high, hydratability reaches specific surface area by force, can rapidly water be inhaled in people's sheet, makes the instantaneous disintegrate of tablet, finally confirms with polyvinylpyrrolidone (PVPP) as disintegrating agent.The starch water absorption and swelling makes disintegration of tablet, does not dissolve after the swelling to form to be uniform aqueous suspension, as suspending agent.It is bigger to adopt polyvinylpyrrolidone to do the particle surface hydrophilic that binding agent makes.The easy label that infiltrates of moisture makes its quick disintegrate stripping behind the tabletting.In certain concentration range, the alcoholic solution concentration of polyvinylpyrrolidone is big more, can make the hydrophobic particle surface hydrophilicity increase, accelerate disintegrate.
(2) fluidizer and lubricant: the fluidizer of these article is micropowder silica gel, in pelletizing press sheet or direct powder compression, all helps improving the flowability of granule or powder.It not only can improve powder, particulate flowability, can also significantly improve the dissolution rate of insoluble drug.Lubricant adopts hydrophilic Pulvis Talci.
(3) surfactant: the medicine crystal formation is different, and its dissolubility and dissolution velocity are also different, for the dissolution rate that further improves medicine need be aided with surfactant, selects polyoxyethylene sorbitan monoleate (Tween80) commonly used to make surfactant.
(4) odor mask: dispersible tablet is generally taken after disintegrate or the dispersion in water, the sand type when taking medicine for minimizing, and adding water solublity mannitol preferably improves mouthfeel.
(5) filler: suitable filler can produce synergism to disintegrating agent, adopts the good microcrystalline Cellulose (MCC) of swellability as filler.
(6) swelling adjuvant: add an amount of sodium alginate, speeding up disintegration of tablet, and make solution have certain viscosity, the unlikely rapid sinking of fine particle that makes dispersible tablet disperse the back to form keeps suspension to have certain stability.
(7) preparation technology: drug micronization is handled, made its particle diameter below 200 orders, direct powder compression is processed the specification of 0.1g/ sheet.
(8) assay:
Instrument: day island proper Tianjin high performance liquid chromatograph;
The hydroxychloroquine sulfate reference substance: Shanghai Westen and Chinese Tranditional Medicine Pharamacentic Co., Ltd produces, content 99.9%, and 105 ℃ are dried to constant weight during use.Get hydroxychloroquine sulfate reference substance 50mg, accurate claim surely, put in the 50ml measuring bottle, with the chromatograph dissolve with methanol and be diluted to graduation mark, shake up, promptly get.
Chromatographic condition: chromatographic column: shim-pack vp-ODS post; Mobile phase: 0.05mol.L
-1Potassium dihydrogen phosphate (containing 1.0% triethylamine)-0.005mol.L
-1The sodium heptanesulfonate methanol solution; Detect wavelength: 343nm; Flow velocity: 1.0ml.min
-1Column temperature: room temperature; Sample size: 20 μ L.
Sample treatment: get 50 of homemade hydroxychloroquine sulfate dispersible tablets, be dried to constant weight, porphyrize, precision takes by weighing 3 parts in an amount of sample (being equivalent to hydroxychloroquine sulfate 50mg), puts respectively in the 50ml measuring bottle, with the chromatograph dissolve with methanol and be diluted to graduation mark, shakes up, and promptly gets.
Measure: get reference substance solution and 3 parts of need testing solutions carry out chromatography, calculate content by external standard method, the result shows that the content of 3 duplicate samples is respectively 95.7%, 95.1%, 96.2%.RSD (relative standard deviation) is respectively 0.80%, 0.88%, 0.90%.
Compared with prior art, technical scheme of the present invention is:
When 1, treating rheumatism, the effective ways that reduce adverse effect are to manage to improve focus kind drug concentrations, reduce the drug level of blood and liver, kidney.The present invention adopts two kinds of new dosage forms, helps improving the bioavailability of hydroxychloroquine sulfate, reduces side effects of pharmaceutical drugs, and it is convenient that the patient is taken.Simultaneously, to patient's individual variation situation, can select different dosage forms.
2, present, the preparation technique of domestic production capsule, dispersible tablet and appointed condition are very ripe, and this invention has good feasibility.
The specific embodiment
Below in conjunction with concrete embodiment to the present invention to further explanation and explanation.
Embodiment 1:
100mg hydroxychloroquine sulfate capsule, contain:
Hydroxychloroquine sulfate crude drug 35mg magnesium stearate 5mg
Pulvis Talci 5mg glycerol 2mg
Adjuvant is: starch, PEG-400
With No. 2 capsules that are filled in behind medicine and the adjuvant mix homogeneously, drug specifications 0.1g/ grain.The quality of capsule detects by the requirement to capsule in the pharmacopeia " rules of preparations ": content assaying method wherein adopts HPLC to measure; Detect wavelength 343nm; With ODS is immobile phase, and mobile phase is potassium dihydrogen phosphate (containing 1.5% triethylamine) and sodium heptanesulfonate methanol solution.The content that records hydroxychloroquine sulfate in the sample is 31.8mg.ml
-1
Embodiment 2:
100mg hydroxychloroquine sulfate dispersible tablet, contain:
Hydroxychloroquine sulfate crude drug 35mg polyvinylpyrrolidone 5mg
Micropowder silica gel 5mg polyoxyethylene sorbitan monoleate 5mg
Adjuvant is: starch, Pulvis Talci, mannitol, microcrystalline Cellulose, sodium alginate.
Preparation technology: with medicine and adjuvant mix homogeneously, micronization processes makes its particle diameter below 200 orders, and direct powder compression is processed the specification of 0.1g/ sheet.Work out to such an extent that the quality standard general rule detects by version Chinese Pharmacopoeia in 2005 to dispersible tablet the hydroxychloroquine sulfate sample of preparation; Content assaying method wherein adopts HPLC to measure; Detect wavelength 343nm; With ODS is immobile phase, and mobile phase is potassium dihydrogen phosphate (containing 1.5% triethylamine) and sodium heptanesulfonate methanol solution.The content that records hydroxychloroquine sulfate in the sample is 32.5mg.ml
-1
Embodiment 3:
Efficacy test---equivalent test in the body:
1, experiment material:
Hydroxychloroquine sulfate capsule (by embodiment 1 gained), hydroxychloroquine sulfate dispersible tablet (by embodiment 2 gained), (Shanghai Westen and Chinese Tranditional Medicine Pharamacentic Co., Ltd produces the hydroxychloroquine sulfate reference substance; Lot number: 20110302); Dehydrated alcohol, chromatograph methanol, distilled water (Drug Manufacturing Room of the court production).Day island proper Tianjin high performance liquid chromatograph; Chromatographic column: shim-pack vp-ODS post.
2, experimental technique:
2.1 model preparation: adopt Pristane to induce preparation lupus erythematosus mouse model, the normal control group will not any processing.
2.2 laboratory animal is divided into groups:
105 mice table of random number methods are divided into 5 groups: normal control group (n=5), model control group (n=25), hydroxychloroquine sulfate Capsules group (n=25), hydroxychloroquine sulfate dispersible tablet group (n=25), hydroxychloroquine sulfate tablet group (n=25).
2.3 medication:
After the modeling success, all zoopery day fasting, model control group gives placebo (starch) 0.4g; The hydroxychloroquine sulfate Capsules group gives hydroxychloroquine sulfate capsule 0.4g; Hydroxychloroquine sulfate dispersible tablet group gives hydroxychloroquine sulfate dispersible tablet 0.4g; Hydroxychloroquine sulfate tablet group gives hydroxychloroquine sulfate sheet 0.4g.1h after the administration, 3h, 12h, 24h, 48h randomly draws 5 mices for every group, and heart blood sampling 1ml puts to death then, collects liver, nephridial tissue, and liquid nitrogen is preserved.
2.4HPLC method is measured the concentration of hydroxychloroquine sulfate
2.4.1 chromatographic condition: chromatographic column: shim-pack vp-ODS post; Mobile phase: 0.05mol.L
-1Potassium dihydrogen phosphate (containing 1.0% triethylamine)-0.005mol.L
-1The sodium heptanesulfonate methanol solution; Detect wavelength: 343nm; Flow velocity: 1.0ml/min; Column temperature: room temperature; Sample size: 20 μ L.
2.4.2 reference substance: Shanghai Westen and Chinese Tranditional Medicine Pharamacentic Co., Ltd produces, content 99.9%, and 105 ℃ are dried to constant weight during use.Get hydroxychloroquine sulfate reference substance 50mg, accurate claim surely, put in the 50mL measuring bottle, with the chromatograph dissolve with methanol and be diluted to graduation mark, shake up, promptly get.
2.4.3 sample treatment: the accurate 0.5ml of absorption sample adds the 10ml centrifuge tube, and adding 10 μ L concentration is 0.204mg.L
-1Metronidazole do in mark, add the 1ml acetone precipitation subsequently, whirlpool 2min, 3000r.min
-1Centrifugal 5min gets supernatant 1ml in the 10ml centrifuge tube, in 50 ℃ of water-baths, uses N
2Volatilize, (6: 4, V/V) 0.1ml added normal hexane 0.4mL again, vibrates, and discards the upper strata normal hexane, takes off layer liquid 20 μ L sample introductions to add dilute hydrochloric acid-ethanol.
3, the result
3.1 the hydroxychloroquine sulfate blood drug level of different preparations in different time is seen table 1.
The hydroxychloroquine sulfate blood drug level of the different preparations of table 1 in different time
3.2 the hydroxychloroquine sulfate blood drug level of the hepatic tissue of different preparations in different time is seen table 2.
The hydroxychloroquine sulfate blood drug level of the hepatic tissue of the different preparations of table 2 in different time
3.3 hydroxychloroquine sulfate blood drug level in the nephridial tissue of different preparations in different time is seen table 3.
Hydroxychloroquine sulfate blood drug level in the nephridial tissue of the different preparations of table 3 in different time
4 conclusions
Conclusion by table 1-3 can know that the blood drug level of hydroxychloroquine sulfate dispersible tablet is the highest, and the hydroxychloroquine sulfate capsule takes second place, and the blood drug level of hydroxychloroquine sulfate sheet is minimum, and its bioavailability is minimum; It is thus clear that novel form of the present invention has increased bioavailability of medicament.In liver, nephridial tissue, the concentration of hydroxychloroquine sulfate sheet will be higher than hydroxychloroquine sulfate dispersible tablet and hydroxychloroquine sulfate capsule, and visible, novel form of the present invention has reduced side effects of pharmaceutical drugs.
Claims (8)
1. a hydroxychloroquine sulfate capsule is characterized in that, comprises the composition of following weight portion in the hydroxychloroquine sulfate capsule of 100 weight portions:
3 parts-8 parts of 30 parts of-40 parts of magnesium stearate of hydroxychloroquine sulfate crude drug
1 part-5 parts of 3 parts of-8 parts of glycerol of Pulvis Talci
All the other are adjuvant.
2. according to the said hydroxychloroquine sulfate capsule of claim 1, it is characterized in that, comprise the composition of following weight portion in the hydroxychloroquine sulfate capsule of 100 weight portions:
5 parts of 23 parts of magnesium stearate of hydroxychloroquine sulfate crude drug
2 parts of 5 parts of glycerol of Pulvis Talci
All the other are adjuvant.
3. according to claim 1 or 2 said hydroxychloroquine sulfate capsules, it is characterized in that said adjuvant is starch and/or PEG400.
4. according to claim 1 or 2 said hydroxychloroquine sulfate capsules, it is characterized in that the moisture content of its content is less than 9%.
5. according to claim 1 or 2 said hydroxychloroquine sulfate capsules, it is characterized in that, is No. 2 capsules, and specification is the 0.1g/ grain.
6. a hydroxychloroquine sulfate dispersible tablet is characterized in that, comprises the composition of following weight portion in the hydroxychloroquine sulfate dispersible tablet of 100 weight portions:
2 parts-8 parts of 30 portions of-40 portions of disintegrating agents of hydroxychloroquine sulfate crude drug
2 parts-8 parts in 2 parts of-8 parts of surfactants of fluidizer
All the other are adjuvant;
Said disintegrating agent is a polyvinylpyrrolidone, and said fluidizer is micropowder silica gel, and said surfactant is a polyoxyethylene sorbitan monoleate;
Said adjuvant is: starch, Pulvis Talci, mannitol, one or more in microcrystalline Cellulose and the sodium alginate.
7. according to the said hydroxychloroquine sulfate dispersible tablet of claim 6, it is characterized in that, comprise the composition of following weight portion in the hydroxychloroquine sulfate dispersible tablet of 100 weight portions:
5 parts of 35 portions of disintegrating agents of hydroxychloroquine sulfate crude drug
5 parts in 5 parts of surfactants of fluidizer
All the other are adjuvant.
8. said hydroxychloroquine sulfate capsule of one of claim 1-5 and claim 6 or the 7 said hydroxychloroquine sulfate dispersible tablets application in the medicine of preparation treatment rheumatoid disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110324985XA CN102349877A (en) | 2011-10-24 | 2011-10-24 | Hydroxychloroquine sulfate capsule, hydroxychloroquine sulfate dispersible tablet and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110324985XA CN102349877A (en) | 2011-10-24 | 2011-10-24 | Hydroxychloroquine sulfate capsule, hydroxychloroquine sulfate dispersible tablet and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102349877A true CN102349877A (en) | 2012-02-15 |
Family
ID=45573596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110324985XA Pending CN102349877A (en) | 2011-10-24 | 2011-10-24 | Hydroxychloroquine sulfate capsule, hydroxychloroquine sulfate dispersible tablet and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102349877A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920674A (en) * | 2012-11-26 | 2013-02-13 | 湖北舒邦药业有限公司 | Technology for preparing hydroxychloroquine sulfate tablets |
| WO2019075229A1 (en) * | 2017-10-13 | 2019-04-18 | Research Triangle Institute | Hydroxychloroquine sulfate formulations and methods for preparation and use thereof |
| CN112494437A (en) * | 2019-10-21 | 2021-03-16 | 上海上药中西制药有限公司 | Hydroxychloroquine compound-containing pharmaceutical composition, tablet and preparation method thereof |
| CN113116840A (en) * | 2021-04-14 | 2021-07-16 | 福建海西新药创制有限公司 | Preparation method of hydroxychloroquine sulfate tablet |
| CN113712933A (en) * | 2020-05-25 | 2021-11-30 | 谢斌 | Production process of hydroxychloroquine sulfate tablets |
-
2011
- 2011-10-24 CN CN201110324985XA patent/CN102349877A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920674A (en) * | 2012-11-26 | 2013-02-13 | 湖北舒邦药业有限公司 | Technology for preparing hydroxychloroquine sulfate tablets |
| CN102920674B (en) * | 2012-11-26 | 2014-04-30 | 远大医药（中国）有限公司 | Technology for preparing hydroxychloroquine sulfate tablets |
| WO2019075229A1 (en) * | 2017-10-13 | 2019-04-18 | Research Triangle Institute | Hydroxychloroquine sulfate formulations and methods for preparation and use thereof |
| CN111201013A (en) * | 2017-10-13 | 2020-05-26 | 研究三角协会 | Hydroxychloroquine sulfate formulations and methods of making and using same |
| EP3694488A4 (en) * | 2017-10-13 | 2021-07-07 | Research Triangle Institute | Hydroxychloroquine sulfate formulations and methods for preparation and use thereof |
| US11648202B2 (en) | 2017-10-13 | 2023-05-16 | Research Triangle Institute | Hydroxychloroquine sulfate formulations and methods for preparation and use thereof |
| CN112494437A (en) * | 2019-10-21 | 2021-03-16 | 上海上药中西制药有限公司 | Hydroxychloroquine compound-containing pharmaceutical composition, tablet and preparation method thereof |
| CN112494437B (en) * | 2019-10-21 | 2023-03-10 | 上海上药中西制药有限公司 | Hydroxychloroquine compound-containing pharmaceutical composition, tablet and preparation method thereof |
| CN113712933A (en) * | 2020-05-25 | 2021-11-30 | 谢斌 | Production process of hydroxychloroquine sulfate tablets |
| CN113116840A (en) * | 2021-04-14 | 2021-07-16 | 福建海西新药创制有限公司 | Preparation method of hydroxychloroquine sulfate tablet |
| CN113116840B (en) * | 2021-04-14 | 2022-09-09 | 福建海西新药创制有限公司 | Preparation method of hydroxychloroquine sulfate tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101984960B (en) | Rizatriptan benzoate capsule and preparation method thereof | |
| CN100393305C (en) | Montelukast oral disintegrating tablet formulation and its preparing method | |
| CN102349877A (en) | Hydroxychloroquine sulfate capsule, hydroxychloroquine sulfate dispersible tablet and application thereof | |
| CN100477991C (en) | Oral formulation of neogambogic acid for treating tumor | |
| CN101229148A (en) | Glonoin Orally disintegrating tablets preparation of and preparing method thereof | |
| CN101869633B (en) | Enteric-coated medicament combination containing epigallocatechin gallate | |
| CN103181923B (en) | Pharmaceutical preparation comprising Repaglinide and preparation method thereof | |
| CN103006594A (en) | Glimepiride composite and preparation method thereof | |
| CN101108230B (en) | Di'ao xinxuekang slow release formulated product and method of preparing the same and use thereof | |
| CN102485226B (en) | Compound artemisinin piperaquine pellet and preparation method thereof | |
| CN104940152A (en) | Pharmaceutical composition containing solifenacin succinate | |
| CN102600149B (en) | Pharmaceutical composition for treating diabetes | |
| CN107213130B (en) | A kind of Entecavir Pharmaceutical composition, preparation method and applications | |
| CN102309538B (en) | Compound lumbricus extract, and preparation process and composition thereof | |
| CN100382807C (en) | Natural medicine composition for preventing and treating metabolic syndrome | |
| CN114533744A (en) | Ticagrelor-aspirin compound pellet preparation and preparation method thereof | |
| CN101647956B (en) | Medicament for treating plague diseases and preparation method thereof | |
| CN101244068B (en) | Hemsleyadin sustained-release preparation | |
| CN101874792B (en) | Phloroglucinol orally disintegrating tablets and preparation method thereof | |
| CN104644558A (en) | Solid dispersion of cilnidipine and preparation method thereof | |
| CN104644601B (en) | Capecitabine tablet | |
| CN100444846C (en) | Dispersion tablet contg. Gynostemma petaphylla total glucosides, and its prepn. method | |
| CN103191071B (en) | Irbesartan dispersible tablet and preparation method thereof | |
| CN103006602B (en) | Quickly-dissolved atorvastatin calcium tablet and preparation method thereof | |
| CN1732926B (en) | Medicine contained soft capsule |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120215 |